Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Hong will help drive strategic growth and technology innovation with over 20 years of experience.
October 15, 2025
By: Rachel Klemovitch
Nona Biosciences (Nona), a global biotechnology company providing integrated solutions from “Idea to IND” (I to ITM), appointed Dr. Di Hong as Chief Executive Officer (CEO). Dr. Hong will be based in Shanghai and report directly to Dr. Jingsong Wang, Chairman of Nona Biosciences.
In this role, Dr. Hong will lead Nona’s next stage of growth by strengthening its highly efficient service system, advancing technology innovation, integrating AI and external investment, and further evolving the business model into a “Service Plus” ecosystem-powered platform. This direction is designed to enhance strategic agility and position the company for long-term leadership in the global biopharmaceutical industry.
Dr. Hong brings over 20 years of leadership experience spanning science, operations, and strategy. Most recently, as CEO of Gaoyue Group (the life science infrastructure platform of Hillhouse), he built a national life science network and established a “Lab-to-Market” ecosystem.
He has also held senior roles at Hua Medicine, Bioduro-Sundia, Amgen, Eli Lilly, and Roche in China, blending global and local expertise across biopharma, CRO, and investment.
This milestone reflects a pivotal step in Nona’s journey to accelerate innovation in antibody discovery and development. Leveraging its proprietary industry-leading Harbour Mice technology platform, Nona has expanded its capabilities into HCAb PLUSTM, the 2.0 version of Harbour Mice.
Dr. Jingsong Wang, Chairman of Nona Biosciences, commented: “We are very pleased to welcome Dr. Di Hong to Nona Biosciences as the new CEO. Dr. Hong’s broad leadership experience across biopharma, CRO, and investment, along with his track record in building innovative ecosystems, make him exceptionally well-suited to lead Nona into its next phase of growth. I am confident that under his leadership, Nona team will further strengthen our technology platforms, expand global partnerships, and advance our vision of becoming a long-term leader in biologics innovation.”
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
